Wanbury Limited

NSE WANBURY.NS

Wanbury Limited Revenue Per Share for the year ending March 31, 2024: USD 2.11

Wanbury Limited Revenue Per Share is USD 2.11 for the year ending March 31, 2024, a 13.42% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Wanbury Limited Revenue Per Share for the year ending March 31, 2023 was USD 1.86, a -10.32% change year over year.
  • Wanbury Limited Revenue Per Share for the year ending March 31, 2022 was USD 2.07, a -1.92% change year over year.
  • Wanbury Limited Revenue Per Share for the year ending March 31, 2021 was USD 2.11, a 5.30% change year over year.
  • Wanbury Limited Revenue Per Share for the year ending March 31, 2020 was USD 2.01, a -14.50% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
SV Wall Street
NSE: WANBURY.NS

Wanbury Limited

CEO Mr. Pradeep Patni
IPO Date Jan. 29, 2007
Location India
Headquarters BSEL Tech Park, B-Wing
Employees 1,491
Sector Healthcare
Industries
Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Similar companies

THEMISMED.NS

Themis Medicare Limited

USD 2.62

1.36%

VIMTALABS.NS

Vimta Labs Limited

USD 9.86

2.71%

VENUSREM.NS

Venus Remedies Limited

USD 3.47

1.60%

XPROINDIA.NS

Xpro India Limited

USD 14.57

1.32%

StockViz Staff

February 2, 2025

Any question? Send us an email